Trial Profile
Phase 1/2 study of REM-001 therapy for the treatment of recurrent basal cell carcinoma in patients with basal cell nevus syndrome
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Apr 2021
Price :
$35
*
At a glance
- Drugs Rostaporfin (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 22 Feb 2018 According to a Adgero Biopharmaceuticals media release, in this trial 14 patients with BCCNS were enrolled and treated with REM-001
- 09 Jan 2017 New trial record